Antiangiogenic therapeutic approaches in multiple myeloma

Domenico Ribatti, Giuseppe Mangialardi, Angelo Vacca

Research output: Contribution to journalArticlepeer-review


Angiogenesis is a constant hallmark of multiple myeloma (MM) progression and has prognostic potential. The pathophysiology of MM-induced angiogenesis involves both direct production of angiogenic cytokines by plasma cells and their induction within the bone marrow microenvironment. An improved understanding of the importance of angiogenesis-related signaling in MM has allowed for the rational use of antiangiogenic therapies in this tumor. This review article summarizes the literature data concerning the employment of the most important antiangiogenic therapeutic agents actually used in preclinical models and clinical settings for the treatment of MM.

Original languageEnglish
Pages (from-to)768-775
Number of pages8
JournalCurrent Cancer Drug Targets
Issue number7
Publication statusPublished - 2012


  • Angiogenesis
  • Antiangiogenesis
  • Bortezomib
  • Lenalinomide
  • Multiple myeloma
  • Thalidomide
  • Thyrosine kinase inhibitors
  • Zoledronic acid

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Cancer Research


Dive into the research topics of 'Antiangiogenic therapeutic approaches in multiple myeloma'. Together they form a unique fingerprint.

Cite this